N J Lassam - JoVE Visualize

Showing results (11-20 of 18) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 18 results.

The EMBO Journal|December 16, 1996

MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6L A Tibbles, Y L Ing, F Kiefer, et al.

Genes, Chromosomes & Cancer|May 1, 1997

Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARFL Liu, A M Goldstein, M A Tucker, et al.

Journal of Virology|February 1, 1981

Protein kinase activity immunoprecipitated from adenovirus infected cells by sera from tumor-bearing hamstersP E Branton, N J Lassam, J F Downey, et al.

The New England Journal of Medicine|March 27, 1998

CDKN2A mutations in multiple primary melanomasJ Monzon, L Liu, H Brill, et al.

Growth Factors (Chur, Switzerland)|January 1, 1994

VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factorB Terman, L Khandke, M Dougher-Vermazan, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1997

Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with gliomaL Gao, L Liu, D van Meyel, et al.

International Journal of Cancer|December 6, 1997

CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal proteinS Sun, P M Pollock, L Liu, et al.

Gene Therapy|August 6, 1999

Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trialA K Stewart, N J Lassam, I C Quirt, et al.

Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 18 results.

The EMBO Journal|December 16, 1996

MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6L A Tibbles, Y L Ing, F Kiefer, et al.

Genes, Chromosomes & Cancer|May 1, 1997

Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARFL Liu, A M Goldstein, M A Tucker, et al.

Journal of Virology|February 1, 1981

Protein kinase activity immunoprecipitated from adenovirus infected cells by sera from tumor-bearing hamstersP E Branton, N J Lassam, J F Downey, et al.

The New England Journal of Medicine|March 27, 1998

CDKN2A mutations in multiple primary melanomasJ Monzon, L Liu, H Brill, et al.

Growth Factors (Chur, Switzerland)|January 1, 1994

VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factorB Terman, L Khandke, M Dougher-Vermazan, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1997

Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with gliomaL Gao, L Liu, D van Meyel, et al.

International Journal of Cancer|December 6, 1997

CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal proteinS Sun, P M Pollock, L Liu, et al.

Gene Therapy|August 6, 1999

Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trialA K Stewart, N J Lassam, I C Quirt, et al.

Pageof 2